OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press9510.17650/1818-8346-2011-6-2-4-7HEMATOLOGIC MALIGNANCIES: DIAGNOSIS, TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ДИАГНОСТИКА, ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯTreatment of patients with refractory chronic lymphocytic leukemia with alemtuzumab, alone or in combination with fludarabineЛечение резистентных больных хроническим лимфолейкозом программами, включающими алемтузумаб в виде монотерапии или в сочетании с флударабиномKataevaE. V.КатаеваЕ. В.
Russian Federation
e.kataeva2010@yandex.ruGolenkovA. K.ГоленковА. К.
Russian Federation
TrifonovaE. V.ТрифоноваЕ. В.
Russian Federation
DudinaG. A.ДудинаГ. А.
Russian Federation
MitinaT. A.МитинаТ. А.
Russian Federation
VysotskayaL. L.ВысоцкаяЛ. Л.
Russian Federation
LutskayaT. D.ЛуцкаяТ. Д.
Russian Federation
BuravtsovaI. V.БуравцоваИ. В.
Russian Federation
GorenkovR. V.ГоренковР. В.
Russian Federation
ChuksinaYu. Yu.ЧуксинаЮ. Ю.
Russian Federation
YazdovskiyV. V.ЯздовскийВ. В.
Russian Federation
M.F. Vladimirsky Moscow Regional Research Clinical InstituteГУ Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского23052011624723072014230720142011https://oncohematology.abvpress.ru/ongm/article/view/95

In present study the immediate and long-term therapy results of 14 patients with refractory chronic lymphocytic leukemia (CLL) are analyzed. Treatment program included alemtuzumab alone or in combination with fludarabine.

В настоящем исследовании изучены непосредственные и отдаленные результаты лечения 14 резистентных больных хроническим лимфолейкозом (ХЛЛ) программами, включающими алемтузумаб в виде монотерапии и в сочетании с флударабином.

chronic lymphocytic leukemiaresistant patientsalemtuzumabfludarabineхронический лимфолейкозрезистентные больныеалемтузумабфлударабин1. Rai K.R., Peterson B.L., Appelbaum F.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–7.Rai K.R., Peterson B.L., Appelbaum F.R. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750–7.2. Leporrior M., Chevret S., Cazin B. et al. Randomized comparison of fludarabin, CAP and CHOP in 938 previously untreatedstage B and C chronic lymphocytic leukemia patients. Blood 2001;98(23):2319–25.Leporrior M., Chevret S., Cazin B. et al. Randomized comparison of fludarabin, CAP and CHOP in 938 previously untreatedstage B and C chronic lymphocytic leukemia patients. Blood 2001;98(23):2319–25.3. Catovsky D., Richard S., Matutes E. et al. Assesment of fludarabin plus cyclophosphamide for patients with chronic lymphocytic leukemia. Lancet 2007;270:230–9.Catovsky D., Richard S., Matutes E. et al. Assesment of fludarabin plus cyclophosphamide for patients with chronic lymphocytic leukemia. Lancet 2007;270:230–9.4. Hallek M., Fingerle-Rowson G., Fink A.M. et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) impruves responses rates and progression-freesurvival (PFS) of previously untreated patients with advanced chronic lymphocytic leukemia. Blood 2008;112:325.Hallek M., Fingerle-Rowson G., Fink A.M. et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) impruves responses rates and progression-freesurvival (PFS) of previously untreated patients with advanced chronic lymphocytic leukemia. Blood 2008;112:325.5. Hillmen P., Skotnicki A.B., Robak T. et al. Alemtuzumab compared with chlorambucil as fist-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;2:5616–23.Hillmen P., Skotnicki A.B., Robak T. et al. Alemtuzumab compared with chlorambucil as fist-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;2:5616–23.6. Kennedy B., Raustron A., Carter C. et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245–7.Kennedy B., Raustron A., Carter C. et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002;99:2245–7.7. Elter T., Borchmann P., Schultz H. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractoryB-cell chronic lymphocytic leukemia: result of a phase II trial. J Clin Oncol 2005;23:7024–31.Elter T., Borchmann P., Schultz H. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractoryB-cell chronic lymphocytic leukemia: result of a phase II trial. J Clin Oncol 2005;23:7024–31.8. Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic ymphocytic leukemia: a report from the Internaional Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446–56.Hallek M., Cheson B.D., Catovsky D. et al. Guidelines for the diagnosis and treatment of chronic ymphocytic leukemia: a report from the Internaional Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute- Working Group 1996 guidelines. Blood 2008;111:5446–56.